RSU grant and exercise update for YD Bio (YDES) director Lu

Rhea-AI Filing Summary

YD Bio Ltd director Lu Shao-Ta reported equity compensation activity and updated share holdings. On June 30, 2026, he exercised 5,749 restricted share units (RSUs) into 5,749 ordinary shares at a stated price of $0.00 per share and received a new grant of 5,749 RSUs.

The RSUs relate to a March 31, 2026 award under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments based on a seven‑day volume‑weighted average price. Following these transactions, Lu holds 7,830 ordinary shares directly and 51,151 ordinary shares indirectly through his spouse.

Insider Trade Summary

5,749 shares exercised/converted

Mixed 4 txns

Insider Lu Shao-Ta

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	5,749	$0.00	--
Exercise	Restricted Share Units	5,749	$0.00	--
Exercise	Ordinary Shares	5,749	$0.00	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Restricted Share Units — 5,749 shares (Direct, null); Ordinary Shares — 7,830 shares (Direct, null); Ordinary Shares — 51,151 shares (Indirect, By Spouse)

Footnotes (1)

1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting. The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").

Key Figures

RSUs exercised: 5,749 units Ordinary shares acquired: 5,749 shares New RSU grant: 5,749 units +4 more

7 metrics

RSUs exercised 5,749 units RSUs converted into ordinary shares on June 30, 2026

Ordinary shares acquired 5,749 shares Received upon RSU exercise at $0.00 per share

New RSU grant 5,749 units Grant under Equity Incentive Plan on March 31, 2026

Grant date fair value $60,000 Aggregate target value of RSU award on March 31, 2026

Quarterly vesting tranche $15,000 Value per quarterly RSU installment using VWAP formula

Direct ordinary shares 7,830 shares Direct holdings after June 30, 2026 transactions

Indirect ordinary shares 51,151 shares Held indirectly through spouse as of June 30, 2026

Key Terms

Restricted Share Units, Equity Incentive Plan, grant date fair value, volume-weighted average price

4 terms

Restricted Share Units financial

"Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

Equity Incentive Plan financial

"The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

grant date fair value financial

"with an aggregate target grant date fair value of $60,000 on March 31, 2026"

The grant date fair value is the estimated dollar worth of a stock-based award (such as stock options or restricted shares) at the exact moment it is given to an employee or contractor. Investors care because companies use that value to record compensation expenses and to show how much potential ownership and earnings dilution those awards could create—think of it as the price tag placed on a gift card when it is handed over so the company can report the cost now.

volume-weighted average price financial

"by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 03:33 PM Accepted by SEC EDGAR 07/01/2026 - 03:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lu Shao-Ta

(Last) (First) (Middle)

C/O YD BIO LIMITED

12F., NO. 3, XINGNAN ST., NANGANG DIST.

(Street)

TAIPEI CITY 115001

(City) (State) (Zip)

TAIWAN

(Country)

2. Issuer Name and Ticker or Trading Symbol
YD Bio Ltd [ YDES ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/30/2026		M		5,749	A	(1)	7,830	D
Ordinary Shares								51,151	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	06/30/2026		A		5,749(2)(3)		(2)	(2)	Ordinary Shares	5,749	$0	5,749	D
Restricted Share Units	(1)	06/30/2026		M			5,749	(2)	(2)	Ordinary Shares	5,749	$0	0	D

Explanation of Responses:

1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.

2. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

3. The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").

	/s/ Shao-Ta Lu	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did YD Bio (YDES) director Lu Shao-Ta report?

Lu Shao-Ta reported exercising 5,749 restricted share units (RSUs) into 5,749 ordinary shares at $0.00 per share and receiving a new grant of 5,749 RSUs. These are equity compensation-related, not open-market purchases or sales.

How many YD Bio (YDES) shares does Lu Shao-Ta own after this Form 4?

After the reported transactions, Lu Shao-Ta holds 7,830 ordinary shares directly and 51,151 ordinary shares indirectly through his spouse. The filing also shows 5,749 RSUs outstanding from the new grant, each representing a right to receive one ordinary share.

What are the terms of the YD Bio (YDES) RSU grant reported in this filing?

The RSUs were granted under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026. They vest in four equal quarterly installments of $15,000 each, determined using a seven‑day volume‑weighted average price.

Did the YD Bio (YDES) director buy or sell shares on the open market?

The Form 4 shows no open-market buys or sells. It reports the exercise of 5,749 RSUs into ordinary shares at $0.00 and a new 5,749-RSU grant, both classified as derivative exercise and grant transactions under the company’s equity incentive plan.

How is the number of YD Bio (YDES) RSUs determined at each vesting date?

For each quarterly vesting, the number of RSUs is calculated by dividing $15,000 by the seven trading‑day volume‑weighted average price of YD Bio’s ordinary shares ending the day before the vesting date, according to the equity incentive plan terms.